High-risk cardiovascular patients: clinical features, comorbidities, and interconnecting mechanisms
KA Schuett, M Lehrke, N Marx… - Frontiers in immunology, 2015 - frontiersin.org
Cardiovascular disease is the leading cause of death in the Western world with an increase
over the last few decades. Atherosclerosis with its different manifestations in the coronary …
over the last few decades. Atherosclerosis with its different manifestations in the coronary …
Vascular inflammation and low‐density lipoproteins: is cholesterol the link? A lesson from the clinical trials
AL Catapano, A Pirillo… - British journal of …, 2017 - Wiley Online Library
For long time, the role of LDL and inflammation in the pathogenesis of atherosclerosis have
been studied independently from each other and only more recently a common platform has …
been studied independently from each other and only more recently a common platform has …
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the …
PM Ridker, JG MacFadyen, T Thuren… - European heart …, 2020 - academic.oup.com
Abstract Aims The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS)
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …
established that targeting inflammation with interleukin-1β (IL-1β) inhibition can significantly …